In a blow to Aussie regenerative medicine company Regeneus Ltd., Japan’s Kyocera Corp. has pulled out of a licensing deal for Regeneus’ lead mesenchymal stem cell (MSC) therapy, Progenza, for osteoarthritis of the knee for the Japan market. Osteoarthritis of the knee is the first indication for Progenza, an allogeneic off-the-shelf adipose-derived MSC therapy.
Prazer Therapeutics Inc. has identified mitogen-activated protein kinase 14 (MAPK14) inhibitors reported to be useful for the treatment of inflammatory disorders.
Researchers from Hefei Industrial Pharmaceutical Institute Co. Ltd. presented the discovery and preclinical evaluation of novel multifunctional inhibitors as potential anti-inflammatory and analgesic agents.
Researchers from Wenzhou Medical University and affiliated organizations have reported the discovery and preclinical evaluation of novel anti-inflammatory compounds. Synthesis and optimization of a new series of 1-(4-(benzylsulfonyl)-2-nitrophenyl) derivatives resulted in the identification of compound [I] as the lead candidate.
UCB SA has identified imidazotriazine derivatives acting as IL-17 modulators reported to be useful for the treatment of autoimmune and inflammatory disorders.
Researchers from Meiji Seika Pharma Co. Ltd. and affiliated organizations reported the discovery and preclinical evaluation of a novel PD-1 agonist antibody, HM-266, being developed for the treatment of various inflammatory disorders, including autoimmune diseases.
Reservoir Neuroscience Inc. has disclosed prostaglandin E2 receptor EP2 subtype (PTGER2; EP2) antagonists reported to be useful for the treatment of inflammation.
University of Copenhagen has divulged 4-hydroxypyridine and 4-hydroxyquinoline derivatives acting as G-protein coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of fibrosis, diabetes, inflammatory and cognitive disorders.
Cantargia AB has completed a GLP toxicity study for its anti-inflammatory IL1RAP-binding antibody CAN-10, showing that CAN-10 was well tolerated when administered over 6 weeks.
RSS
